Literature DB >> 31636122

Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens.

Samantha M Ervin1, Hao Li2, Lauren Lim1, Lee R Roberts3, Xue Liang3, Sridhar Mani2, Matthew R Redinbo4.   

Abstract

Gut microbial β-glucuronidase (GUS) enzymes have been suggested to be involved in the estrobolome, the collection of microbial reactions involving estrogens. Furthermore, bacterial GUS enzymes within the gastrointestinal tract have been postulated to be a contributing factor in hormone-driven cancers. However, to date, there has been no experimental evidence to support these hypotheses. Here we provide the first in vitro analysis of the ability of 35 human gut microbial GUS enzymes to reactivate two distinct estrogen glucuronides, estrone-3-glucuronide and estradiol-17-glucuronide, to estrone and estradiol, respectively. We show that certain members within the Loop 1, mini-Loop 1, and FMN-binding classes of gut microbial GUS enzymes can reactivate estrogens from their inactive glucuronides. We provide molecular details of key interactions that facilitate these catalytic processes and present the structures of two novel human gut microbial GUS enzymes related to the estrobolome. Further, we demonstrate that estrogen reactivation by Loop 1 bacterial GUS enzymes can be inhibited both in purified enzymes and in fecal preparations of mixed murine fecal microbiota. Finally, however, despite these in vitro and ex vivo data, we show that a Loop 1 GUS-specific inhibitor is not capable of reducing the development of tumors in the PyMT mouse model of breast cancer. These findings validate that gut microbial GUS enzymes participate in the estrobolome but also suggest that the estrobolome is a multidimensional set of processes on-going within the mammalian gastrointestinal tract that likely involves many enzymes, including several distinct types of GUS proteins.
© 2019 Ervin et al.

Entities:  

Keywords:  GI microbiota; X-ray crystallography; beta-glucuronidase; breast cancer; enzyme structure; estrobolome; estrogen; gut microbiome; hormone reactivation; structural biology

Mesh:

Substances:

Year:  2019        PMID: 31636122      PMCID: PMC6901331          DOI: 10.1074/jbc.RA119.010950

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  47 in total

Review 1.  Estrogen metabolism by conjugation.

Authors:  R Raftogianis; C Creveling; R Weinshilboum; J Weisz
Journal:  J Natl Cancer Inst Monogr       Date:  2000

2.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

3.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

4.  Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

Authors:  Bret D Wallace; Hongwei Wang; Kimberly T Lane; John E Scott; Jillian Orans; Ja Seol Koo; Madhukumar Venkatesh; Christian Jobin; Li-An Yeh; Sridhar Mani; Matthew R Redinbo
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

Review 5.  P450 enzymes of estrogen metabolism.

Authors:  C P Martucci; J Fishman
Journal:  Pharmacol Ther       Date:  1993 Feb-Mar       Impact factor: 12.310

Review 6.  Functional role of estrogen metabolism in target cells: review and perspectives.

Authors:  B T Zhu; A H Conney
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

Review 7.  Breast cancer metastasis: markers and models.

Authors:  Britta Weigelt; Johannes L Peterse; Laura J van 't Veer
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

8.  Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer.

Authors:  Eleanor G Rogan; Alaa F Badawi; Prabu D Devanesan; Jane L Meza; James A Edney; William W West; Sheila M Higginbotham; Ercole L Cavalieri
Journal:  Carcinogenesis       Date:  2003-04       Impact factor: 4.944

9.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception.

Authors:  Samuel J Pellock; Benjamin C Creekmore; William G Walton; Naimee Mehta; Kristen A Biernat; Andrew P Cesmat; Yamuna Ariyarathna; Zachary D Dunn; Bo Li; Jian Jin; Lindsey I James; Matthew R Redinbo
Journal:  ACS Cent Sci       Date:  2018-07-12       Impact factor: 14.553

View more
  38 in total

Review 1.  Endocrine disruptors and gut microbiome interactions.

Authors:  R Hampl; L Stárka
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

Review 2.  The interaction between gut microbiome and anti-tumor drug therapy.

Authors:  Chen Fu; Ziting Yang; Jiankun Yu; Minjie Wei
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

3.  Alterations to microbial secretome by estrogen may contribute to sex bias in irritable bowel syndrome.

Authors:  Lesha Pretorius; Anton du Preez Van Staden; Johannes J Van der Merwe; Natasha Henning; Carine Smith
Journal:  Inflammopharmacology       Date:  2022-01-13       Impact factor: 4.473

Review 4.  Gut microbiota homeostasis restoration may become a novel therapy for breast cancer.

Authors:  Zhi-Peng Feng; Hong-Yi Xin; Ze-Wei Zhang; Chen-Guang Liu; Zheng Yang; Hua You; Hong-Wu Xin
Journal:  Invest New Drugs       Date:  2021-01-17       Impact factor: 3.850

Review 5.  The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions-Evidence for Estrogen as an Immunomodulator.

Authors:  Jayshree R S
Journal:  Front Cell Infect Microbiol       Date:  2021-04-30       Impact factor: 5.293

6.  Alternaria alternata Mycotoxins Activate the Aryl Hydrocarbon Receptor and Nrf2-ARE Pathway to Alter the Structure and Immune Response of Colon Epithelial Cells.

Authors:  Julia Groestlinger; Veronika Spindler; Gudrun Pahlke; Michael Rychlik; Giorgia Del Favero; Doris Marko
Journal:  Chem Res Toxicol       Date:  2022-04-11       Impact factor: 3.973

Review 7.  Dietary Approaches to Women's Sexual and Reproductive Health.

Authors:  Rashmi Kudesia; Megan Alexander; Mahima Gulati; Anne Kennard; Michelle Tollefson
Journal:  Am J Lifestyle Med       Date:  2021-05-08

Review 8.  Intricate Connections between the Microbiota and Endometriosis.

Authors:  Irene Jiang; Paul J Yong; Catherine Allaire; Mohamed A Bedaiwy
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 9.  Targeting obesity-related dysfunction in hormonally driven cancers.

Authors:  Maria M Rubinstein; Kristy A Brown; Neil M Iyengar
Journal:  Br J Cancer       Date:  2021-04-28       Impact factor: 7.640

Review 10.  Gut and vaginal microbiomes on steroids: implications for women's health.

Authors:  Madeline E Graham; William G Herbert; Stephanie D Song; Harshini N Raman; Jade E Zhu; Paulina E Gonzalez; Marina R S Walther-António; Marc J Tetel
Journal:  Trends Endocrinol Metab       Date:  2021-05-25       Impact factor: 10.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.